Interim FDG
combined DS and ΔSUV(max)
interim response
non-Hodgkin lymphoma
survival
treatment guidance
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
25
09
2022
revised:
13
11
2022
accepted:
20
11
2022
pubmed:
26
12
2022
medline:
31
1
2023
entrez:
25
12
2022
Statut:
ppublish
Résumé
Interim response evaluation by We included 85 patients diagnosed with DLBCL and uniformly treated with standard protocols. iPET with DS of 1-3 and/or ΔSUV iPET positivity, measured by DS or ΔSUV Our study suggests that combined DS and ΔSUV
Identifiants
pubmed: 36567213
pii: S2152-2650(22)01743-8
doi: 10.1016/j.clml.2022.11.009
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e107-e116Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.